A detailed history of Hm Payson & CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hm Payson & CO holds 7,075 shares of VRTX stock, worth $3.29 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
7,075
Previous 19,405 63.54%
Holding current value
$3.29 Million
Previous $9.1 Million 63.83%
% of portfolio
0.06%
Previous 0.17%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$460.0 - $505.78 $5.67 Million - $6.24 Million
-12,330 Reduced 63.54%
7,075 $3.29 Million
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $6.83 Million - $8.44 Million
17,389 Added 862.55%
19,405 $9.1 Million
Q1 2024

Jun 20, 2024

SELL
$407.69 - $446.08 $2,446 - $2,676
-6 Reduced 0.3%
2,016 $842,000
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $677,425 - $811,093
1,975 Added 4202.13%
2,022 $822,000
Q3 2023

Nov 06, 2023

BUY
$338.18 - $362.46 $8,454 - $9,061
25 Added 113.64%
47 $16,000
Q1 2023

Apr 18, 2023

BUY
$283.23 - $323.1 $6,231 - $7,108
22 New
22 $6,000
Q3 2022

Oct 25, 2022

SELL
$273.83 - $305.53 $821 - $916
-3 Reduced 20.0%
12 $3,000
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $704 - $877
3 Added 25.0%
15 $4,000
Q1 2022

May 12, 2022

BUY
$221.42 - $260.97 $2,657 - $3,131
12 New
12 $3,000
Q4 2021

Feb 15, 2022

SELL
$177.01 - $223.45 $6,195 - $7,820
-35 Closed
0 $0
Q3 2021

Nov 30, 2021

BUY
$181.39 - $202.99 $6,348 - $7,104
35 New
35 $6,000
Q2 2021

Aug 17, 2021

SELL
$187.49 - $221.1 $20,061 - $23,657
-107 Closed
0 $0
Q1 2021

Jun 15, 2021

SELL
$207.02 - $241.31 $7,659 - $8,928
-37 Reduced 25.69%
107 $23,000
Q3 2019

Nov 12, 2019

SELL
$166.23 - $187.09 $7,812 - $8,793
-47 Reduced 24.61%
144 $24,000
Q2 2019

Aug 15, 2019

BUY
$164.61 - $190.37 $31,440 - $36,360
191 New
191 $35,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Hm Payson & CO Portfolio

Follow Hm Payson & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hm Payson & CO, based on Form 13F filings with the SEC.

News

Stay updated on Hm Payson & CO with notifications on news.